Effect of teriparatide on bone mineral density and bone markers in the real life: Argentine experience

GUELMAN R; GARCIA ML; FARIAS V; VARSAVSKY ML; SALERNI H; REY P; KARLSBRUM S; GIACOIA E; CONSTANZO PR; OLIVERI B; LUCAS S; SANCHEZ A; SARLI MA; ZANCHETTA MB; PEMROU V; LARRAOUDÉ M SILVIA

Congreso; WCO-IOF ESCEO; 2019

Evaluate the effect of teriparatide (TPTD) on bone mineral density (BMD) and bone markersunder clinical practice conditions in specialized centers.Methodology: Cross-sectional study of 257 postmenopausal women treated with TPTD for at least12 months. We considered: serum calcium, PTH, 25OHD, alkaline phosphatase (AP), bone AP(bAP), osteocalcin (BPG), C-terminal telopeptide (CTX) and urinary deoxypyridinoline (Dpyr). Inaddition, lumbar spine (LS), femoral neck (FN) and total hip (TH) BMD (g/cm2) was evaluated byDXA (Lunar Prodigy). Data were expressed as mean±SD and were analyzed with Wilcoxon test vsbasal (*p